Berlin (ddp). Pharmaceutical expenditures of the statutory health insurance funds threaten this year according to the national organization of Betriebskrankenkassen (BKK) up to 19 percent compared to 2004 rise. «The financial recovery for pharmaceutical expenditures is finished since the beginning of 2005 clearly», the CEO of the BKK Bundesverband, Wolfgang Schmeinck said on Tuesday in Berlin. According to estimates of the BKK Association on the basis of the figures of the first half, you could be spending in 2005 about 3.5 to 4 billion euros of the EUR 21 billion from the previous year. In the households of all statutory health insurance an increase of 5.8 per cent was been scheduled end of 2004 but for this year only, Schmeinck added. Nevertheless led higher pharmaceutical expenditures, as well as the current also «out» expenditure in the hospital sector does not mean that the statutory health insurance funds on average would have to raise their contributions in the current year. Rather will the current contribution rate level of its assessment to «the next year extend». As key reasons for the increase of medicines, the BKK Association called «not comprehensible volume increases» and «Prescription of patent-protected analog products, so new and expensive drugs without therapeutic progress», and the reduction of the abatement of the manufacturer. Even if not all the causes of the medical profession could be attributed to, deceive the Kassenärztliche Confederation (KBV) as well as the Kassenärztlichen associations (KV) for the amount of expenditure increases «direct responsibility», criticized Schmeinck. You would have to support doctors with «Individual Pharmakotherapie advice», demanded the BKK Bundesverband. Also, a practical proposal for the control of medicines on the table is the so-called bonus-malus system.